
Release date: 2026-05-20 13:47:50 Article From: Lucius Laos Recommended: 19
Crizotinib is contraindicated in the following situations: hypersensitivity to crizotinib or any other ingredients in the capsule (such as colloidal anhydrous silica, microcrystalline cellulose, gelatin, titanium dioxide, etc.). Allergic reactions may manifest as rash, dyspnea, or more severe systemic reactions. Patients should ensure they have no known history of allergies.
Before starting treatment, you must inform your doctor of the following conditions: moderate or severe liver disease; any history of lung problems (as crizotinib may cause a lung inflammation-like reaction, leading to dyspnea, cough, or fever); a diagnosis of prolonged QT interval on ECG (a type of heart rhythm disorder); slow pulse; history of gastrointestinal perforation, diverticulitis, or abdominal tumor metastases; presence of visual disturbances (flashes, blurred vision, or double vision); severe renal impairment. If any of these conditions apply, your doctor may need to perform additional tests or adjust the treatment plan.
While taking crizotinib or after completing treatment, if you experience any of the following severe symptoms, contact your doctor immediately: severe abdominal pain or lower abdominal pain, fever, chills, shortness of breath, palpitations, partial or complete vision loss in one or both eyes, changes in bowel habits. Additionally, if you develop new or worsening dyspnea, productive or dry cough, unusual fatigue, yellowing of the skin or eyes, dark urine, nausea and vomiting, loss of appetite, right-sided abdominal pain, skin itching, or unusual bruising, seek urgent medical attention. Your doctor may monitor liver and kidney function through blood tests and adjust the dose or discontinue treatment based on the results.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3252025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643